☆ 4.6 Review

The Black Hole: CAR T Cell Therapy in AML

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children

Svea Stratmann et al.

Summary: Through mass spectrometry-based proteomics, researchers analyzed the proteomic changes in acute myeloid leukemia patients during disease progression. They found that the proteomic profile at relapse was enriched for mitochondrial ribosomal proteins and subunits of the respiratory chain complex, indicating the importance of energy metabolism in disease progression. Changes in levels of inflammatory markers and anti-inflammatory proteins were also associated with disease development. Additionally, novel peptides were detected through a proteogenomic approach, providing potential biomarkers and druggable targets.

LEUKEMIA (2023)

添加到收藏夹

Review Oncology

Present and Future Role of Immune Targets in Acute Myeloid Leukemia

Daniela Damiani et al.

Summary: Despite advances in understanding the biological mechanisms of AML, the prognosis remains poor. The bone marrow microenvironment and immune system play important roles in AML cell persistence and can be targeted for novel therapies. Potential immune-based treatments include monoclonal antibodies, immune checkpoint inhibitors, and cellular therapies. However, identifying optimal targets on leukemic stem cells remains a challenge, impacting the results of ongoing clinical trials.

CANCERS (2023)

添加到收藏夹

Article Hematology

Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia

Danielle C. Kirkey et al.

Summary: Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer-testis antigen that can be targeted for immunotherapy in acute myeloid leukemia (AML). Researchers developed a novel approach using a chimeric antigen receptor (CAR) construct to target PRAME in AML, and demonstrated its efficacy in vitro and in in vivo models. The PRAME-specific CAR T cells showed target-specific and HLA-mediated activity, leading to leukemia clearance and improved survival.

BLOOD ADVANCES (2023)

添加到收藏夹

Review Immunology

Synthetic receptors for logic gated T cell recognition and function

Sylvain Simon et al.

Summary: This review discusses recent advances in T cell engineering that may overcome barriers to successful immune cell therapy by mimicking natural signaling pathways to accurately target tumor cells and regulate effector functions.

CURRENT OPINION IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells

Yi Liu et al.

Summary: Immunotherapies, such as CAR T cells and ADCs, have greatly improved cancer treatment, especially in lymphoid malignancies. The lack of a tumor-specific target antigen has limited the application of targeted immunotherapy in AML patients. A third-generation CAR T-cell product targeting CD33 showed significant anti-leukemia activity in AML and potential for genome-edited stem cell transplantation approaches.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia

Mark B. Leick et al.

Summary: This study demonstrates the development of an enhanced CD70-targeted CAR using orthogonal approaches to improve binding avidity and expansion of CAR-T cells, showing increased in vivo activity in AML models.

CANCER CELL (2022)

添加到收藏夹

Article Cell & Tissue Engineering

Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy

Pinar Ataca Atilla et al.

Summary: This study demonstrates that combinatorial targeting of CD33 or CD123 and CLL-1 using CAR T cells can effectively control the growth of heterogeneous AML tumors and improve survival rates.

CYTOTHERAPY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

Andy G. X. Zeng et al.

Summary: A study found that the composition of leukemia cell hierarchy is associated with treatment response and drug sensitivity. By analyzing the transcriptomes of over 1,000 patients, the researchers identified four classes of leukemia cell hierarchy: Primitive, Mature, GMP, and Intermediate. Variation in hierarchy composition along the Primitive versus GMP or Primitive versus Mature axes was associated with response to chemotherapy or drug sensitivity profiles of targeted therapies.

NATURE MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia

Mayumi Sugita et al.

Summary: This study reports the design and characterization of allogeneic CD123-targeted CAR-T cells as a therapeutic approach for acute myeloid leukemia.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia

Nawid Albinger et al.

Summary: This study introduced the generation of CD33-targeted CAR-modified NK cells using BaEV-LVs, demonstrating enhanced cytotoxic activity against AML cells in vitro and potential anti-leukemic effects in xenograft mouse models.

BLOOD CANCER JOURNAL (2022)

添加到收藏夹

Article Oncology

Emerging CAR T Cell Strategies for the Treatment of AML

Paresh Vishwasrao et al.

Summary: CAR-T cell therapy is a promising cancer treatment method, but it also brings about some immune-related toxicities. Impressive results have been achieved in treating B cell hematological malignancies, but further research is needed for other hematological malignancies. This article summarizes the findings from preclinical and human studies of CAR-T cell therapy and discusses new treatment targets.

CANCERS (2022)

添加到收藏夹

Review Oncology

Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges

Synat Kang et al.

Summary: The cytogenetic abnormalities and molecular mutations in AML present treatment challenges. CAR-T cell therapy has shown promise in leukemia treatment, but an optimal target antigen has not been found for AML. TCR-redirected T cells provide a broader range of therapeutic targets by targeting intracellular antigens presented by HLA molecules. WT1 antigen-specific TCR-T cells have had positive clinical outcomes in AML, but AML can escape immune elimination through immunosuppressive factors.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia

Kening Li et al.

Summary: This study utilized single-cell RNA sequencing to dissect the cellular states and transcriptional heterogeneity of AML bone marrow samples. It revealed that quiescent stem-like cells (QSCs) were involved in chemoresistance and poor outcomes of AML, and these cells could be reprogrammed from proliferating stem/progenitor-like cells (PSPs) during chemotherapy.

LEUKEMIA (2022)

添加到收藏夹

Article Oncology

Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML.

Todd Michael Cooper et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia

Han Dong et al.

Summary: Acute myeloid leukemia (AML) is difficult to treat due to a lack of tumor-specific targets for immune-based therapies. Recent studies have shown that natural killer (NK) cells exhibit innate memory and enhanced antitumor activity when activated with IL-12 and IL-18. This study demonstrates that arming CIML NK cells with a neoepitope-specific CAR significantly improves their antitumor responses to NPM1-mutated AML and avoids off-target toxicity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

添加到收藏夹

Article Oncology

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia

Rim Trad et al.

Summary: This study identified IL-1RAP as a potential target for AML treatment, as it is overexpressed on the surface of leukemic stem cells (LSCs). The researchers demonstrated the effectiveness of IL-1RAP CAR T-cell therapy against AML cell lines and primary cells from patients, suggesting it as a promising strategy for AML treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML

Thomas Koehnke et al.

Summary: This study optimized the Cell Surface Capture protocol to directly investigate primary AML patient samples and applied it to generate the AML surfaceome. The curated AML surfaceome was further enriched using mutational burden data from hematologic cancers, resulting in a set of potential target antigens. Validation in a separate cohort of AML patient samples confirmed the most promising novel candidate markers, including CD148, ITGA4, and Integrin beta-7.

BIOMARKER RESEARCH (2022)

添加到收藏夹

Review Oncology

Pathogenic Mechanisms in Acute Myeloid Leukemia

Sohini Chakraborty et al.

Summary: Acute myeloid leukemia (AML) is the most common form of leukemia in adults, leading to the highest number of annual leukemia-associated deaths in the USA. Recent advancements in high-throughput sequencing techniques and disease models have improved our understanding of the molecular mechanisms that cause AML. These mechanisms can be classified into cell-intrinsic and cell-extrinsic categories, and studying them provides new opportunities for treating and preventing AML.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

添加到收藏夹

Article Cell & Tissue Engineering

Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells

Mark Gurney et al.

Summary: This study reports a promising application of transposon engineering to donor-derived NK cells and emphasizes the importance of feeder-mediated NK cell activation and expansion in the current protocol. The approach enabled clinically relevant expansion of NK cells and expression of chimeric antigen receptor (CAR), and the CAR-NK cells effectively targeted AML cells expressing CLL-1. Additionally, the concurrent delivery of CRISPR/Cas9 cargo enhanced the cytotoxicity and altered the phenotype of NK cells by knockout of the NK cell cytokine checkpoint cytokine-inducible SH2-containing protein (CIS) gene.

CYTOTHERAPY (2022)

添加到收藏夹

Article Oncology

Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis

Hui Zhang et al.

Summary: This study conducted a clinical trial of autologous anti-CLL1 CAR-T cell immunotherapy in children with relapsed or refractory AML to evaluate the safety and preliminary efficacy of the treatment. The results showed that anti-CLL1 CAR-T cell immunotherapy exhibited good tolerance and effectiveness for treating children with R/R-AML.

LEUKEMIA (2022)

添加到收藏夹

Review Oncology

The Potential Role of 3D In Vitro Acute Myeloid Leukemia Culture Models in Understanding Drug Resistance in Leukemia Stem Cells

Basil Al-Kaabneh et al.

Summary: This article reviews the recent advancements in using 3D in vitro models to study AML and highlights their role as potential platforms for understanding resistance and relapse in AML.

CANCERS (2022)

添加到收藏夹

Article Immunology

Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity

Simone A. Minnie et al.

Summary: This study elucidates the mechanisms of resistance of tumors to T cell-mediated antitumor effects after alloBMT and proposes an immunotherapy approach targeting stem-like memory T cells to enhance antitumor immunity.

SCIENCE IMMUNOLOGY (2022)

添加到收藏夹

Meeting Abstract Hematology

Off-the-Shelf CD33 CAR-NK Cell Therapy for Relapse/Refractory AML: First-in-Human, Phase I Trial

Ruihao Huang et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Sascha Haubner et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Oncology

SINGLE-CELL TRANSCRIPTOMIC ATLAS-GUIDED DEVELOPMENT OF CHIMERIC ANTIGEN-RECEPTOR (CAR) T CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

A. Gottschlich et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

NK cells and ILCs in tumor immunotherapy

Simona Sivori et al.

Summary: Innate immune cells, especially NK cells, play an important role in tumor immunotherapy by controlling tumor growth and metastasis. Various approaches have been developed, such as using IL-15 to improve NK cell function and utilizing NK cell engagers to activate NK cells. Additionally, NK cells may express inhibitory checkpoints like PD-1, which can be targeted for therapeutic use against certain tumors.

MOLECULAR ASPECTS OF MEDICINE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch

Walid Warda et al.

Summary: Although chimeric antigen receptor (CAR) T cell immunotherapies have been successful in treating B malignancies, tumor cells can develop resistance through antigen masking or inactivation of CAR T cells. Researchers have validated this epitope-masking resistance model in acute myeloid leukemia and found that decreased epitope density of IL-1RAP leads to resistance to CAR T cells.

CANCER GENE THERAPY (2021)

添加到收藏夹

Meeting Abstract Hematology

Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer

Jennifer A. Foltz et al.

BLOOD (2021)

添加到收藏夹

Article Oncology

A modular and controllable T cell therapy platform for acute myeloid leukemia

Mohamed-Reda Benmebarek et al.

Summary: A modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to AML has been developed, combining synthetic agonistic receptor (SAR) -transduced T cells with AML-targeting tandem single chain variable fragment (scFv) constructs. This platform shows selective killing of AML cells and persistent responses in xenograft models, indicating its potential for further translation in AML treatment.

LEUKEMIA (2021)

添加到收藏夹

Review Oncology

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

Eryn Blass et al.

Summary: Immunotherapy has revolutionized cancer treatment with the development of immune-checkpoint inhibitors and personalized neoantigen vaccines. These vaccines trigger specific T cell responses against individual patient's tumors, showing promising tumor-specific immunogenicity and antitumor activity.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Letter Hematology

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke et al.

BLOOD (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential

Mansour Poorebrahim et al.

Summary: Neoepitopes or neoantigens are unique mutations in a patient's tumor that can be used for tumor treatment. Adoptive therapies based on T cell receptor engineering or CARs show promise in eradicating tumors while minimizing damage to normal tissues. The focus is on neoepitopes and addressing current limitations in harnessing this approach for effective and specific anti-tumor therapy.

CANCER GENE THERAPY (2021)

添加到收藏夹

Article Hematology

Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia

Antonio Pierini et al.

Summary: A novel HLA-haploidentical HSCT strategy, combining an age-adapted myeloablative conditioning regimen with regulatory and conventional T-cell adoptive immunotherapy, resulted in a significant improvement in cGVHD/relapse-free survival rate in 50 AML patients.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer et al.

Summary: CD70 is a promising target antigen for AML treatment, and CD70-CAR T cells demonstrate good proliferation and antitumor activity in vitro and in vivo for CD70-positive AML patients, showing potential as a new treatment strategy.

BLOOD (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

Sabrina Prommersberger et al.

Summary: Clinical development of CAR-T-cell therapy has been advanced by synthetic biology, genetic engineering, and clinical-grade manufacturing, with the goal of providing safe, effective, and economically sustainable treatment. The CARAMBA project aims to demonstrate virus-free CAR gene transfer using advanced SB transposon technology, potentially improving vector procurement, CAR-T manufacturing, and distribution. The project focuses on utilizing SB-based CAR-T cells targeting the SLAMF7 antigen in multiple myeloma, with promising preclinical results indicating potent anti-myeloma activity.

GENE THERAPY (2021)

添加到收藏夹

Article Immunology

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes

Gregory Ehx et al.

Summary: An analysis of the immunopeptidome in AML patients identified tumor-specific antigens (TSAs) which were derived from non-coding genomic regions and associated with intron retention and epigenetic changes. These TSAs may serve as attractive targets for AML immunotherapy.

IMMUNITY (2021)

添加到收藏夹

Article Oncology

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities

Ilias Christodoulou et al.

Summary: The study demonstrates that engineering NK cells to express CARs and IL-15 can enhance their anti-AML activity. However, this modification also comes with potential systemic toxicities.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Letter Oncology

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Francesco Paolo Tambaro et al.

LEUKEMIA (2021)

添加到收藏夹

Article Cell Biology

Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models

Dina Schneider et al.

Summary: Researchers have developed a trispecific duoCAR-T cell strategy to effectively target B cell malignancies with different antigens, showing superior efficacy compared to traditional monoCAR-T cells. The combination of intracellular signaling motifs plays a crucial role in the antitumor effects of duoCAR-T cells.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Hematology

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Hardikkumar Jetani et al.

Summary: Siglec-6 can serve as a novel target for CAR T cell therapy in AML, effectively eliminating AML cells without affecting normal hematopoietic stem cells. This therapy may also be applicable to CLL, with limited on-target/off-tumor reactivity on normal mature hematopoietic cells.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Oncology

The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis.

Hui Zhang et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Qingya Cui et al.

Summary: The study demonstrated the potential efficacy and safety of CD38-targeted CAR-T cells in treating relapsed AML patients by eliminating CD38 positive blasts without off-target effects, although the risk of relapse still exists.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Cell & Tissue Engineering

Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients

Faroogh Marofi et al.

Summary: AML is a life-threatening disease with low survival rates, but CAR T cell therapy shows promising results as a novel treatment method, especially in the treatment of hematological cancers. Gradual advancements in targeting AML antigens with CAR T cell therapy have led to more effective and specific therapies with impressive clinical outcomes.

STEM CELL RESEARCH & THERAPY (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Emily J. Pomeroy et al.

MOLECULAR THERAPY (2020)

添加到收藏夹

Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy

Rebecca Epperly et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

Simon Loff et al.

MOLECULAR THERAPY-ONCOLYTICS (2020)

添加到收藏夹

Review Oncology

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers

Sareetha Kailayangiri et al.

CANCERS (2020)

添加到收藏夹

Review Immunology

The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies

Tobias Bald et al.

NATURE IMMUNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome

Lu Jiang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

Martina Geiger et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, Research & Experimental

CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia

Melinda A. Biernacki et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Sleeping Beauty engineered CAR T cells achieve antileukemic activity without severe toxicities

Chiara F. Magnani et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Immunology

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells

Liangshun You et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Immunology

HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study

Peter van Balen et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia

Pinar Ataca Atilla et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Hematology

Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS

Anna Stengel et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Hematology

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Kevin A. Hay et al.

BLOOD (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity

Peter van Galen et al.

CELL (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting RIPK1 for the treatment of human diseases

Alexei Degterev et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

添加到收藏夹

Review Medicine, General & Internal

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)

Susanne Hofmann et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Aude G. Chapuis et al.

NATURE MEDICINE (2019)

添加到收藏夹

Meeting Abstract Hematology

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin L. Costello et al.

BLOOD (2019)

添加到收藏夹

Meeting Abstract Hematology

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Emma C. Morris et al.

BLOOD (2019)

添加到收藏夹

Article Immunology

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy

Lucia Fernandez et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts

Carter M. Suryadevara et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia

Dyantha van der Lee et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia

Diogo Gomes-Silva et al.

MOLECULAR THERAPY (2019)

添加到收藏夹

Review Oncology

Acute myeloid leukemia and NK cells: two warriors confront each other

Aroa Baragano Raneros et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG plus AML

Sun Yao et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

Miriam Y. Kim et al.

CELL (2018)

添加到收藏夹

Article Oncology

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia

Jessica C. Petrov et al.

LEUKEMIA (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells

Wei Xiong et al.

MOLECULAR THERAPY (2018)

添加到收藏夹

Meeting Abstract Oncology

Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

Tapan M. Kadia et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Cell Biology

Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system

Michael Hudecek et al.

CURRENT OPINION IN GENETICS & DEVELOPMENT (2018)

添加到收藏夹

Article Oncology

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Regina Jitschin et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Meeting Abstract Hematology

First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial

Fang Liu et al.

BLOOD (2018)

添加到收藏夹

Article Immunology

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells

Dimitris Karamitros et al.

NATURE IMMUNOLOGY (2018)

添加到收藏夹

Review Hematology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Doehner et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients

J. Pan et al.

LEUKEMIA (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia

Silvia Arcangeli et al.

MOLECULAR THERAPY (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1

Haruko Tashiro et al.

MOLECULAR THERAPY (2017)

添加到收藏夹

Article Hematology

Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS

Isao Tawara et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML

Fabiana Perna et al.

CANCER CELL (2017)

添加到收藏夹

Article Hematology

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia

Sarah K. Tasian et al.

BLOOD (2017)

添加到收藏夹

Review Hematology

Therapeutic targeting of acute myeloid leukemia stem cells

Daniel A. Pollyea et al.

BLOOD (2017)

添加到收藏夹

Review Hematology

Biology and relevance of human acute myeloid leukemia stem cells

Daniel Thomas et al.

BLOOD (2017)

添加到收藏夹

Review Oncology

Harnessing the immune system in acute myeloid leukaemia

Rebecca Austin et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)

添加到收藏夹

Review Immunology

Chimeric antigen receptors: driving immunology towards synthetic biology

Michel Sadelain

CURRENT OPINION IN IMMUNOLOGY (2016)

添加到收藏夹

Article Genetics & Heredity

Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution

M. Ryan Corces et al.

NATURE GENETICS (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

Sheng Li et al.

NATURE MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Matthew S. Davids et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Eric Tran et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Cell Biology

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

Rizwan Romee et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors

Daniel T. Harris et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2016)

添加到收藏夹

Article Oncology

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

M. Cartellieri et al.

BLOOD CANCER JOURNAL (2016)

添加到收藏夹

Article Education, Scientific Disciplines

Mutations in AML: prognostic and therapeutic implications

Courtney D. DiNardo et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)

添加到收藏夹

Meeting Abstract Hematology

Allogeneic Tcra/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts

Monica L. Guzman et al.

BLOOD (2016)

添加到收藏夹

Meeting Abstract Hematology

Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Naval Daver et al.

BLOOD (2016)

添加到收藏夹

Article Hematology

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Soranobu Ninomiya et al.

BLOOD (2015)

添加到收藏夹

Review Immunology

Targeting cancer-specific mutations by T cell receptor gene therapy

Thomas Blankenstein et al.

CURRENT OPINION IN IMMUNOLOGY (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

Cyrille J. Cohen et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Article Oncology

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

S. S. Kenderian et al.

LEUKEMIA (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

Quan-shun Wang et al.

MOLECULAR THERAPY (2015)

添加到收藏夹

Review Medicine, General & Internal

Acute Myeloid Leukemia

Hartmut Doehner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Multidisciplinary Sciences

Adoptive cell transfer as personalized immunotherapy for human cancer

Steven A. Rosenberg et al.

SCIENCE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Eliezer M. Van Allen et al.

SCIENCE (2015)

添加到收藏夹

Article Hematology

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

R. Coleman Lindsley et al.

BLOOD (2015)

添加到收藏夹

Review Immunology

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity

Jacques C. Mbongue et al.

VACCINES (2015)

添加到收藏夹

Review Hematology

The past and future of CD33 as therapeutic target in acute myeloid leukemia

George S. Laszlo et al.

BLOOD REVIEWS (2014)

添加到收藏夹

Review Cell & Tissue Engineering

Evolution of the Cancer Stem Cell Model

Antonija Kreso et al.

CELL STEM CELL (2014)

添加到收藏夹

Article Cell & Tissue Engineering

Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche

Maher Hanoun et al.

CELL STEM CELL (2014)

添加到收藏夹

Review Oncology

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

Pierre G. Coulie et al.

NATURE REVIEWS CANCER (2014)

添加到收藏夹

Article Hematology

Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia

Mareike Rickmann et al.

ANNALS OF HEMATOLOGY (2013)

添加到收藏夹

Article Hematology

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

Isabel Ben-Batalla et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

Francis Mussai et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

Monica Casucci et al.

BLOOD (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

David S. Ritchie et al.

MOLECULAR THERAPY (2013)

添加到收藏夹

Article Medicine, General & Internal

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

Timothy J. Ley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Oncology

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Julie Schanz et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Cell Biology

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

Max Jan et al.

SCIENCE TRANSLATIONAL MEDICINE (2012)

添加到收藏夹

Article Hematology

Differential niche and Wnt requirements during acute myeloid leukemia progression

Steven W. Lane et al.

BLOOD (2011)

添加到收藏夹

Article Oncology

PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

Avital L. Amir et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Article Hematology

Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies

Marleen M. van Loenen et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)

添加到收藏夹

Article Hematology

Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells

Andreas Hofmann et al.

BLOOD (2010)

添加到收藏夹

Article Hematology

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

Qing Zhou et al.

BLOOD (2009)

添加到收藏夹

Review Hematology

B lymphocytes: how they develop and function

Tucker W. LeBien et al.

BLOOD (2008)

添加到收藏夹

Article Hematology

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells

Claudine Graf et al.

BLOOD (2007)

添加到收藏夹

Article Oncology

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

Cyrille J. Cohen et al.

CANCER RESEARCH (2006)

添加到收藏夹

Article Hematology

An inducible caspase 9 safety switch for T-cell therapy

KC Straathof et al.

BLOOD (2005)

添加到收藏夹

Review Oncology

Leukaemia stem cells and the evolution of cancer-stem-cell research

BJP Huntly et al.

NATURE REVIEWS CANCER (2005)

添加到收藏夹

Review Immunology

Exploiting T cell receptor genes for cancer immunotherapy

S Xue et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)

添加到收藏夹

Article Oncology

C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia

ABH Bakker et al.

CANCER RESEARCH (2004)

添加到收藏夹

Article Multidisciplinary Sciences

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

WAE Marijt et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

S Dias et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

添加到收藏夹

Article Oncology

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

CT Jordan et al.

LEUKEMIA (2000)

添加到收藏夹

Article Oncology

Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells

LJ Bendall et al.

LEUKEMIA (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.